Market – Market Outlook & Trends
The Global Antidiabetics
Market estimated at USD 63.5 billion in 2019, is expected to reach USD 121.40
Billion in 2026, at a CAGR of 9.70 % during the projection period. The
prevalence of diabetes among increasing individuals across the globe, the
requirement for treatment without side effects and rising acceptance
antidiabetic drugs, in emerging and advanced nations drive the market for
antidiabetic drugs. The strong growth of antidiabetics is mainly attributed to
its advantages and functioning that allow fewer chances of severe glycemic
conditions because of limited glucose variability. Besides, the ability of
antidiabetic pumps to store data can be further used to analyze data in
determining treatment schedules. Such advantages are likely to induce the
antidiabetics market. The pharma companies spend substantially on R & D for
drug development to discover medicines with minimal side effects providing
impetus to the market.
Market – Overview
Diabetes is a
long-lasting metabolic disease wherein the body is either unable to produce
insulin (Type-1) or cannot absorb insulin (Type-2). Diabetes is one kind of
metabolic illness in which the individual has high blood glucose (blood sugar)
due to insufficient insulin production or the body's cells not responding well
to insulin. Patients with high sugar levels experience various symptoms such as
increased thirst (polydipsia), weight loss, augmented hunger (polyphagia), and
recurrent and sweet-smelling urination (polyuria). If it is not cured within
time, diabetes causes various severe and chronic life-threatening
Diabetes may occur in any
age irrespective of gender. Overweight people with unhealthy diets and less
physical activity are more prone to diabetes. Diabetes may lead to many severe
conditions such as sightlessness, amputations, kidney failure, and advanced
risk of death. The anti-diabetics market comprises drugs used for curing
diabetes mellitus, and, these drugs are known as oral
hypoglycemic/antihyperglycemic agents. The anti-diabetics market has developed
remarkably over the current years due to the growing occurrence of diabetes
mellitus. Thus, complete treatment for diabetes has become the focal point of
care due to the burgeoning diabetic ailments among all age groups, including
middle age groups and children across all income clusters globally.
Growing investment in
drug development to manage diabetes
According to the European
Society of Cardiology, the diabetic population is expected to reach 628.6
million by 2045. The treatment of diabetes needs appropriate interference and
drug administration as per the conditions of patients. Advancement in
antidiabetic drugs has led to maximum success rates and fewer difficulties. And
due to that, numerous new drugs including, dipeptidyl peptidase-4 inhibitors,
discriminatory sodium-glucose cotransporter-2 inhibitors and exclusive
peroxisome proliferator-activated receptor agonists are in the growth stage.
Besides, the introduction of new devices has improved the chances for
combination treatments. The public and structural efforts to innovate diabetes
drugs expand the market size immediately.
High success rates
associated with insulin antidiabetic products
The success rate
associated with insulin products is expected to provide high market potential.
The drug segment is sub-categorized into Alpha-glucosidase inhibitors, Biguanides,
Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl
Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport
Proteins) inhibitors and Thiazolidinedione. The edge of short-acting analog has
improved its post-prandial glucose-controlling ability in type 1 and type 2
diabetic patients and, the segment is likely to witness unparalleled growth
during the analysis with a surge in the type-2 diabetic patient pool.
The high cost of
High costs of diabetes
medications do not only compel the patients to live with this condition but
also restrict the healthcare capability of medical professionals. Even the most
effective antidiabetic medications recommended by the astute and thorough
medical professionals are not affordable for a patient with modest income.
Impact of COVID-19 in
The COVID-19 eruption has
affected nearly 100 countries severely, and it has been declared a Public
Health Emergency by WHO. The economies across the world are witnessing slump
with a slowdown in every sector. The widespread Coronavirus has also negatively
influenced the Antidiabetic Medication market in 2020 by a noticeable decline
in demand and production and disrupting supply chains. However, as the Antidiabetic
market is related to healthcare, its growth will not be obstructed for a long
time due to pandemic.
The AntiDiabetic Market
is divided into Insulin segment and Drug segment based on product. Insulin
segment is again divided into fast-acting analog, long-acting analog, premixed
insulin, short-acting analog, middle acting insulin segments. The Insulin
segment secured a notable market share in 2019 and, is anticipated to continue
the same at a remarkable CAGR of 12.4% during the forthcoming period.
Antidiabetic Drug segment is subclassified into Alpha-glycosidase Inhibitors,
Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists,
Meglitinides, DPP-IV (Dipeptidyl Peptidase) inhibitors, SGLT-II (Sodium-Glucose
Transport Proteins) inhibitors and Thiazolidinedione. It is also expected to
grow at a moderate rate during the projected period.
Based on the
administration route, the market is subdivided into Insulin Syringe/Insulin
Pen, Insulin Pump, Intravenous Infusion and Oral. The Insulin Pump segment is
anticipated to register strong growth with CAGR of 11% during the forthcoming
Based on region, Global
Antidiabetics Market is segmented by key regions— North America, Europe, Asia
Pacific, South America, and the Middle East & Africa.
Market: Regional Insights
Ø In December 2019, Mankind Pharmaceuticals signed a collaborative
marketing agreement with Glenmark Pharmaceuticals for Remoglifozin, an
antidiabetic drug, in India. This has allowed both companies to expand their
business in the Asia Pacific region.
Ø In February 2018, Cipla collaborated with Novartis and Johnson
& Johnson to market their antidiabetic drugs to strengthen its market
position by widening its base.
Scope of the Report
Historical data – 2016-2018
Base Year – 2019
2020 – 2026
Revenue in USD Billion
Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Japan, South
Korea, China, India, UAE, South Africa, Saudi Arabia.
By Product, By Patient
Population, By Route of Administration, By Region
Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson &
Johnson, Mankind Pharma Ltd., Meantidiabeticc., Novartis AG, Novo Nordisk
A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd and others.
ü Rapid Acting
ü Long Acting
ü Premixed Insulin
ü Short Acting
ü Intermediate Acting
Ø Drug Class
ü Alpha-Glucosidase Inhibitors
ü GLP-1 Agonist
ü DPP-4 Inhibitors
By Patient Population
By Route of Administration
Ø Insulin Syringe/Insulin Pen
Ø Insulin Pump
Ø Intravenous Infusion
Ø North America
Ø Asia Pacific
Ø South America
Ø Middle East & Africa
The objective of the Study:
Ø To analyze and estimate the Global Electric Boat Market size, in terms of value.
Ø To examine the market segmentation carefully and estimate the
market size, in terms of value, based on the region by segmenting the Global Antidiabetics Market into five regions,
namely, North America, Europe, Asia Pacific, Rest of the World and their leading
Ø To outline, categorize and project the Global Antidiabetics Market based on Product, Patient Population,
Route of Administration and Region.
Ø To examine competitive developments in product and devices used
for administration across different age-groups within the Global Antidiabetics Market.
Ø To highlight market dynamics such as drivers, restraints,
opportunities, and challenges and their impact.
Ø To provide a detailed competitive landscape, including major
players, their strategic profiles, and market shares.
Business Questions Answered by the Report:
Ø How will the market drivers, restraints, and opportunities
affect the market dynamics?
Ø What will be the market size in terms of value and volume and
market statistics with a detailed classification?
Ø Which segment dominates the market or region, and which one will
be the fastest-growing, and why?
Ø Who are the key players in the market, and what is their share?
Ø What is the strategy adopted by key players, and how does it
affect the existing and new players?
Customization Scope for the Client:
Client satisfaction is our first and last priority, and that is
why BlueWeave Consulting offers customization as per client’s specific needs.
The following customization options are available for the report:
Ø Additional Company Information
Ø Detail Analysis of five additional companies
Ø Additional country analysis
Ø Detailed segment analysis